Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors

V. Lenko, L. Bialesova, D. Macejova, P. Bujdak, J. Breza, J. Brtko

. 2013 ; 157 (4) : 316-324. [pub] 20130911

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc15026684

BACKGROUND: Renal cell carcinoma (RCC) is a urologic malignancy with a steady rise in incidence and high mortality rate. Between 60 to 70% of patients with renal cell carcinoma can only be cured with surgery but despite advances in early diagnostis, in around 20-30% of cases there is metastasis. For these patients, chemotherapy and radiotherapy are ineffective and hence the prognosis is poor. Retinoids are biologically active compounds of either natural or synthetic origin that are involved in complex physiological and developmental processes in many tissues including cell proliferation and activation of tumour suppression genes. This article reviews the role of retinoids and their cognate nuclear retinoid/rexinoid receptors in relation to renal cell carcinoma. METHODS: A literature search using ScienceDirect and Medline with a focus on the relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors. RESULTS: Use of retinoids/rexinoids in the treatment of locally advanced and metastatic RCC significantly prolongs median time of tumour progression and overall survival of patients. Combination therapy with other preparations has greater efficacy than treatment with retinoids alone. Patient survival can be predicted on the basis of the expression of different all-trans retinoic acid receptor (RAR) and 9-cis retinoic acid receptor (RXR) subtypes. CONCLUSIONS: Since nuclear retinoid receptors play a crucial role as ligand-activated, DNA binding, trans-acting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes, retinoids might be an alternative approach for the treatment of renal cell carcinoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15026684
003      
CZ-PrNML
005      
20150818085845.0
007      
ta
008      
150811s2013 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2013.060 $2 doi
035    __
$a (PubMed)24077234
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Lenko, Vladimir $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Urology, University Hospital Bratislava, St. Cyril and Method Hospital, Bratislava, Slovak Republic $7 _AN083796
245    14
$a The relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors / $c V. Lenko, L. Bialesova, D. Macejova, P. Bujdak, J. Breza, J. Brtko
520    9_
$a BACKGROUND: Renal cell carcinoma (RCC) is a urologic malignancy with a steady rise in incidence and high mortality rate. Between 60 to 70% of patients with renal cell carcinoma can only be cured with surgery but despite advances in early diagnostis, in around 20-30% of cases there is metastasis. For these patients, chemotherapy and radiotherapy are ineffective and hence the prognosis is poor. Retinoids are biologically active compounds of either natural or synthetic origin that are involved in complex physiological and developmental processes in many tissues including cell proliferation and activation of tumour suppression genes. This article reviews the role of retinoids and their cognate nuclear retinoid/rexinoid receptors in relation to renal cell carcinoma. METHODS: A literature search using ScienceDirect and Medline with a focus on the relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors. RESULTS: Use of retinoids/rexinoids in the treatment of locally advanced and metastatic RCC significantly prolongs median time of tumour progression and overall survival of patients. Combination therapy with other preparations has greater efficacy than treatment with retinoids alone. Patient survival can be predicted on the basis of the expression of different all-trans retinoic acid receptor (RAR) and 9-cis retinoic acid receptor (RXR) subtypes. CONCLUSIONS: Since nuclear retinoid receptors play a crucial role as ligand-activated, DNA binding, trans-acting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes, retinoids might be an alternative approach for the treatment of renal cell carcinoma.
650    _2
$a karcinom z renálních buněk $x etiologie $7 D002292
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x etiologie $7 D007680
650    _2
$a receptory cytoplazmatické a nukleární $x fyziologie $7 D018160
650    _2
$a receptory kyseliny retinové $x fyziologie $7 D018168
650    _2
$a retinoidní X receptory $x fyziologie $7 D047488
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Bialešová, Lucia $7 _AN083797 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Macejová, Dana $7 xx0061612 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
700    1_
$a Bujdák, Peter $7 xx0126325 $u Department of Urology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
700    1_
$a Breza, Ján, $7 _BN004042 $u Department of Urology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
700    1_
$a Brtko, Július $7 xx0121874 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 157, č. 4 (2013), s. 316-324
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20150811 $b ABA008
991    __
$a 20150812132412 $b ABA008
999    __
$a ok $b bmc $g 1087894 $s 909720
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 157 $c 4 $d 316-324 $e 20130911 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20150811

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...